Year-end Report 1 January – 31 December 2025: Dedicare strengthens its competitive position in a continued challenging market

Dedicare reported Q4 net sales of SEK 361.8m (down 7.0% YoY) and FY 2025 net sales of SEK 1,454.8m (down 15.4% YoY); FY EBITA was SEK 50.5m (3.5% margin) or SEK 54.6m adjusted, and profit for the year was SEK 33.1m with EPS of SEK 3.46. Management cut costs by SEK 40m versus 2024, saw margin improvement from efficiencies, completed the We Care acquisition which boosted Denmark, and noted Norway represented ~60% of Q4 sales (currency-adjusted declines cited). The board proposed a reduced ordinary dividend of SEK 1.75 per share and revised the long-term EBITA margin target down to 6.0% (from 7%), reflecting a cautious outlook despite a solid balance sheet and signs of market stabilisation.

Analysis

Market structure: Dedicare’s results signal a market where demand for traditional healthcare staffing is contracting while specialized life‑science and therapist placements are growing. Norway (60% of Q4 sales) remains the revenue engine — a continued double‑digit, currency‑adjusted decline would quickly transfer market share to lower‑cost competitors; Denmark’s post‑acquisition lift shows M&A can temporarily reprice local margins. Pricing power is weakening (EBITA margin down to 3.5% FY), implying continued margin compression across small/mid‑cap staffing peers; monitor NOK/SEK movements as ~60% revenue exposure to Norway creates FX sensitivity that will affect reported EBITDA.

Risk assessment: Tail risks include abrupt regulatory limits on agency nurses/doctors (UK/Nordics) or a failed integration of We Care producing >SEK 10–20m one‑off charges; liquidity risk is low (equity/assets ~48%) but earnings volatility is high — expect headline swings in the next 30–90 days around Q1 bookings. Immediate risks (days) are share‑price knee‑jerk on FY figures; short term (weeks/months) hinge on Q1 sales trend; long term (quarters+) depends on achieving the new 6.0% EBITA target and converting cost cuts (SEK 40m) into persistent savings.

Trade implications: Tactical long if share price falls >10% intraday (establish 2–3% portfolio weight, target 12–24 months), because payout ratio ~50% (dividend SEK 1.75, EPS SEK 3.46) and a margin recovery to 5.5–6.0% would re‑rate the stock. Pair trade: long Dedicare vs short UK/NHS‑exposed recruiters (e.g., Hays PLC LON:HAS) 1:1 hedged for market beta over 3–9 months; use 3–6 month covered calls to harvest premium if initiating or buy 6–9 month 25% OTM calls as downside‑contingent upside. Rotate out of pure NHS‑dependent staffing names into life‑science staffing specialists (12–24 month horizon).

Contrarian angles: The market underprices the de‑risking effect of geographic and service diversification — if Sweden stabilizes and Denmark’s acquisition scales, EPS can outpace revenue growth (operational gearing). The Board’s lower 6% target may be conservative; if management converts SEK 40m cost cuts into permanent savings, adjusted EBITA of SEK ~55m implies upside of 20–30% vs current market pricing assumptions. Unintended consequence: the lower target could cap near‑term multiple expansion even as fundamentals improve, so time sizing and option structures (calls vs covered calls) are critical to capture asymmetric upside.

Key Decisions for Investors

• If Dedicare (Nasdaq Stockholm: DEDI) share price drops >10% from today’s level, establish a 2–3% long position sized to portfolio risk tolerance; set stop‑loss at 12% and target 18–30% total return over 12–24 months assuming margin recovery to 5.5–6.0% and stable payout (dividend SEK 1.75).
• Implement a relative‑value pair trade: long Dedicare (DEDI) vs short UK/NHS‑exposed recruiter Hays PLC (LON:HAS) in equal notional amounts for a 3–9 month trade; hedge market beta and expect outperformance if Nordic specialty placements stabilize while NHS demand remains constrained.
• If already long Dedicare, sell 3–6 month covered calls ~10–15% OTM to monetize current dividend and reduce net cost; alternatively buy 6–9 month 25% OTM calls (small size, 0.5–1% portfolio) after any >8% sell‑off to capture asymmetric upside.
• Reduce/avoid new exposure to pure NHS/UK‑centric staffing names for the next 6–12 months and reallocate 3–5% of staffing allocations into Nordic life‑science staffing specialists and listed companies with <30% revenue exposure to UK/NHS, pending Q1 booking trends and any regulatory announcements within 60 days.